Bioceltix S.A. (WSE:BCX)

Market Cap	517.07M
Revenue (ttm)	n/a
Net Income (ttm)	-14.49M
Shares Out	4.92M
EPS (ttm)	-3.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,675
Average Volume	3,832
Open	104.60
Previous Close	105.00
Day's Range	103.20 - 105.00
52-Week Range	66.00 - 129.00
Beta	1.37
RSI	51.41
Earnings Date	Sep 18, 2025

About Bioceltix

Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was incorporated in 2018 and is based in Wroclaw, Poland.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 36
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: BCX